Don't miss any news, subscribe to our press releases.
Due to legal restrictions, access to this part of the website is limited. We therefore ask you to read the following information and provide the following confirmation each time you wish to access these restricted web pages. Your confirmation must be accurate and fair.
Please select the country where you are resident: * USAAustraliaCanadaNew ZealandHong KongJapanSouth KoreaSingaporeSwitzerlandSwedenSouth Africaanother country outside the EEAanother country in the EEA
Indicate the country you are in: * USAAustraliaCanadaNew ZealandHong KongJapanSouth KoreaSingaporeSwitzerlandSwedenSouth Africaanother country outside the EEAanother country in the EEA
Next page
The information contained herein is not intended for, and may not be, directly or indirectly, in whole or in part, disseminated, published or distributed in or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland, the United States or any other jurisdiction where to do so would constitute a violation of local securities laws or regulations. Access to the information and documentation on this part of the website is restricted by law. We therefore ask you to read the following information and provide the following confirmation each time you wish to access these restricted web pages. Your confirmation must be accurate and fair.
The information on this part of Sprint Bioscience AB (publ)'s ("The company's") website is (a) not intended for, and may not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons residing or located in the United States (including its territories and provinces, any state of the United States and the District of Columbia (the "United States")), Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland or South Korea, or any other jurisdiction where such action may constitute a violation of local securities laws or regulations and (b) does not constitute an offer to sell, or the solicitation of an offer to buy or purchase, shares or other securities of the Company in the United States, Australia, Canada, Belarus, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action may constitute a violation of local securities laws or regulations in such jurisdiction.
Securities of the Company referred to on this website ("The securities") has not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act") and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with all applicable securities laws of any state or other jurisdiction of the United States. Furthermore, the securities have not been and will not be registered under any applicable securities laws of Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland, South Korea or any other jurisdiction in which such action may be unlawful or require registration or other action, and accordingly the securities may not be offered or sold to or within, or for the account or benefit of, any person who is a resident or located in Australia, Canada, Belarus, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action may be unlawful or may require registration or other action.
The company assesses that it conducts activities worthy of protection according to the Act (2023:560) on the review of foreign direct investments ("FDI laws"In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the regulation and that the investment may be notifiable. In the event that an investment is notifiable, it must be notified to the Inspectorate for Strategic Products (ISP) prior to its implementation. Each investor should consult an independent legal advisor on the possible application of the FDI Law in relation to the rights issue for the individual investor.
Access to the information and documents on the following websites may be illegal in certain jurisdictions and only certain categories of persons may be permitted to access such information and documents. Any person wishing to access the documents on this part of the Company's website must first satisfy themselves that they are not subject to any local laws or regulations which prohibit or restrict their right to access this website, or whether their acquisition of securities requires registration or approval. Such registration or approval has not been obtained and will not be obtained. The Company accepts no responsibility for any person's breach of applicable laws and regulations.
If you are not authorized to access the information and documentation on this website, or if in doubt as to whether you have such authorization, please leave this website.
I therefore certify that:
I agree to I do not accept
The information contained in this part of the website is not intended for persons residing or located in any jurisdiction (including the United States, Australia, Canada, New Zealand, Hong Kong, Japan, South Korea, Singapore, Switzerland, South Africa) where distribution of the information contained in this part of the website would require additional measures to be taken or would be contrary to the laws or regulations of that jurisdiction. You have either not complied with this condition or have not provided the necessary confirmations. You cannot therefore access this part of the website.
